Need an investment idea? Check out Popular Stocks and S2O Stock Screener.

Market Price

330.97 

-0.11 0.0%

as of Mar 22 '23

52 Week Range:

257.60 384.44


Stock Analyzer Tutorials

S2O Stock Analyzer - General Info

General Info


type: video (mp4); length: 3:30

Demonstrates how to use Stock Analyzer, shows how to analyze a stock and explains in detail "General Info" section of the Stock Analyzer result page.

S2O Stock Analyzer - Financial Statements

Financial Statements


type: video (mp4); length: 5:10

Explains information presented in the Financial Statements section of the S2O Stock Analyzer: financial statements charts, absolute values and growth rates.

S2O Stock Analyzer - Growth Grade and Financial Ratios

Growth Grade and Financial Ratios


type: video (mp4); length: 5:09

Demonstrates how to use Growth Grade & Financial Ratios section; shows the difference between historical and year-over-year Growth Grade on the real life example.

S2O Stock Analyzer - Value Price

Value Price


type: video (mp4); length: 6:03

Demonstrates how to use Value Price (intrinsic value) and the Graham Number, MOS (margin of safety) and IRT - Investment Recovery Time; explains 3 different projection models used to compute value price - pessimistic, moderate and optimistic.

S2O Stock Analyzer - Price Charts

Price Charts


type: video (mp4); length: 8:34

Demonstrates basic rules of how to read a candlestick chart, long and short term moving averages, stochastic, MACD and relative strength (RS) charts. Explains how bull or bear market condition is computed.

General Info

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Financial Statements

The charts below show selected Annual and Quarterly Financial Data.

The purpose of these charts is to discover long and short term change dynamics. When numbers are growing year after year in the annual statements chart, the business become stronger and stronger and this is a good sign.

Quarterly Data Chart can be used to do a short term analysis. It makes sense to pay attention to the quarterly dynamics and do not wait for the next yearly statement. We should be alerted if we see that quarterly numbers are going down.

You can check "Annual Financial Statements" and "Quarterly Financial Statements" sections for exact numbers and growth rates.

Annual Statements

On a charts below the Line shows absolute values and the Bar chart shows Year-Over-Year Growth Rate for selected financial statement item. A consistent GROWTH is generally considered necessary to fund future growth from within a business.
NOTE: Growth Rate is not provided if either the latest period or the year-ago period contains a net loss. (source: WSJ Digest of Earnings)
TIP! move your mouse pointer over bar or a circle on any chart below to see details.

Financial Statements

Income Statement



 

Cash Flow Statement



 

Balance Sheet



 

Liquidity Ratios

Current Ratio


 

Current Ratio measures the ability to meet short term obligations. Generally accepted standard is 2 (current assets should be 2 times or 200% of current liabilities).

Quick Ratio


 

Measures immediate liquidity or the cash available to cover immediate liabilities. A safe margin would be at least 1 (100%).

Financial Leverage


 

Defined as total assets divided by total shareholders' equity. The higher the ratio, the more debt a company uses in its capital structure.

Profitability Ratios

ROA


 

Return on Assets (ROA) measures the income (profit) that is generated by the use of the assets of the business.

ROE


 

Return on Equity (ROE) is a measure of profitability that calculates how many dollars of profit a company generates with each dollar of shareholders equity. ROE is sometimes called "return on net worth."

ROIC


 

The Return on Invested Capital (ROIC) measure gives a sense of how well a company is using its money to generate returns. Some investors use this figure as a final evaluation to determine whether or not to invest in a company.

Annual Statements

Item Name Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18 Dec '19 Dec '20 Dec '21
Equity (BVPS) 10.04
10.58
11.00
13.09
12.61
13.40
11.34
10.82
3.16
4.12
7.16
growth rate 5.4% 4.0% 19.0% -3.7% 6.3% -15.4% -4.6% -70.8% 30.4% 73.8%
Earnings BIT 3,965.96
4,010.43
6,025.80
5,999.40
7,101.40
8,177.50
growth rate 1.1% 7.0% -0.4% 18.4% 15.2%
Avg.PE 10.64
13.30
6.77
6.77
6.77
53.69
growth rate 25.0% -49.1% 0.0% 0.0% 41.2%
ROA 13.45
12.01
13.45
6.60
6.62
7.36
-0.49
7.27
20.00
14.42
11.70
growth rate -10.7% 12.0% -50.9% 0.3% 11.2% -100.0% 100.0% 175.1% -27.9% -18.9%
ROE 33.49
28.89
28.92
14.49
16.09
19.16
-1.59
30.18
133.78
150.18
76.35
growth rate -13.7% 0.1% -49.9% 11.0% 19.1% -100.0% 100.0% 343.3% 12.3% -49.2%
ROIC 22.24
20.30
21.87
10.43
10.75
11.95
-0.68
13.91
41.94
31.85
24.39
growth rate -8.7% 7.7% -52.3% 3.1% 11.2% -100.0% 100.0% 201.5% -24.1% -23.4%
Cur. Ratio 1.60
1.55
1.47
1.09
1.53
1.37
1.32
1.73
1.16
1.40
1.23
growth rate -3.1% -5.2% -25.9% 40.4% -10.5% -3.7% 31.1% -33.0% 20.7% -12.1%
Quick Ratio 1.25
1.14
1.06
0.77
1.04
0.98
0.91
1.20
0.68
0.85
0.80
growth rate -8.8% -7.0% -27.4% 35.1% -5.8% -7.1% 31.9% -43.3% 25.0% -5.9%
Leverage 2.49
2.33
2.00
2.42
2.44
2.77
3.88
4.47
15.07
8.27
5.44
growth rate -6.4% -14.2% 21.0% 0.8% 13.5% 40.1% 15.2% 237.1% -45.1% -34.2%
Balance Sheet Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18 Dec '19 Dec '20 Dec '21
Acct.Receivable 2,775.99
2,574.29
2,649.98
5,696.30
5,523.10
6,887.90
8,112.50
growth rate -7.3% 2.9% 16.5% -3.0% 24.7% 17.8%
Acct.Payable 1,207.10
1,405.30
1,606.70
1,670.60
growth rate 16.4% 14.3% 4.0%
Cur.Assets 10,993.91
10,060.66
10,111.59
20,549.60
13,709.60
17,462.10
18,452.40
growth rate -8.5% 0.5% 15.2% -33.3% 27.4% 5.7%
Total Assets 25,971.90
26,542.19
27,197.90
43,908.40
39,286.10
46,633.10
48,806.00
growth rate 2.2% 2.5% 10.1% -10.5% 18.7% 4.7%
Cash 4,569.80
3,100.91
2,955.38
7,320.70
2,337.50
3,657.10
3,818.50
growth rate -32.1% -4.7% 19.9% -68.1% 56.5% 4.4%
Inventory 1,774.53
2,039.96
2,259.86
3,098.10
3,190.70
3,980.30
3,886.00
growth rate 15.0% 10.8% 6.5% 3.0% 24.8% -2.4%
Cur.Liabilities 6,891.08
6,473.34
6,880.05
11,888.10
11,775.20
12,481.60
15,052.70
growth rate -6.1% 6.3% 11.6% -1.0% 6.0% 20.6%
Liabilities 15,523.13
15,149.36
13,593.51
32,999.30
36,587.00
40,807.90
39,651.20
growth rate -2.4% -10.3% 19.4% 10.9% 11.5% -2.8%
LT Debt 4,216.56
4,258.77
3,240.95
9,241.20
13,843.70
16,784.50
15,387.00
growth rate 1.0% -23.9% 23.3% 49.8% 21.2% -8.3%
Equity 10,448.78
11,392.83
13,604.39
9,828.70
2,606.90
5,641.60
8,979.20
growth rate 9.0% 19.4% -6.3% -73.5% 116.4% 59.2%
Common Shares 1,114.00
1,117.00
1,085.00
1,074.00
1,066.00
1,062.00
1,052.00
661.00
598.80
598.20
596.30
growth rate 0.3% -2.9% -1.0% -0.7% -0.4% -0.9% -37.2% -9.4% -0.1% -0.3%
Cash Flow Statement Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18 Dec '19 Dec '20 Dec '21
Capital Expenditures 498.99
681.63
642.51
1,210.60
1,033.90
1,387.90
1,309.80
growth rate 36.6% -5.7% 13.5% -14.6% 34.2% -5.6%
Cash Dividends 1,682.17
1,687.80
1,636.33
2,311.80
2,409.80
2,687.10
3,086.80
growth rate 0.3% -3.1% 7.2% 4.2% 11.5% 14.9%
Cash From OA 5,582.14
4,093.18
4,425.13
5,524.50
4,836.60
6,499.60
7,260.70
growth rate -26.7% 8.1% 4.5% -12.5% 34.4% 11.7%
FCF per Share 4.05
3.22
3.06
2.36
1.27
2.10
2.96
2.47
2.48
4.57
4.46
growth rate -20.5% -5.0% -22.9% -46.2% 65.4% 41.0% -16.6% 0.4% 84.3% -2.4%
FCF 5,542.00
4,261.00
4,641.00
2,801.00
1,146.00
3,759.00
3,452.00
2,506.00
3,483.00
4,471.00
5,388.00
growth rate -23.1% 8.9% -39.7% -59.1% 228.0% -8.2% -27.4% 39.0% 28.4% 20.5%
Income Statement Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18 Dec '19 Dec '20 Dec '21
Sales 18,739.46
17,440.78
17,834.07
21,493.30
22,319.50
24,539.80
28,318.40
growth rate -6.9% 2.3% 3.8% 3.8% 10.0% 15.4%
Op.Income 4,127.67
3,652.91
4,143.80
6,025.80
5,999.40
7,101.40
8,177.50
growth rate -11.5% 13.4% 7.8% -0.4% 18.4% 15.2%
IBT 4,127.67
4,172.97
4,544.18
3,680.10
5,265.90
7,229.90
6,155.50
growth rate 1.1% 8.9% -4.1% 43.1% 37.3% -14.9%
Net Income 3,354.69
3,154.76
3,614.79
3,232.00
8,318.40
6,193.70
5,581.70
growth rate -6.0% 14.6% -2.2% 157.4% -25.5% -9.9%
EPS 3.90
3.66
4.32
2.23
2.26
2.58
-0.19
3.13
8.89
6.79
6.12
growth rate -6.2% 18.0% -48.4% 1.4% 14.2% -100.0% 100.0% 184.0% -23.6% -9.9%
Gross Profit 14,829.07
13,739.80
14,046.98
16,811.60
17,598.30
19,056.50
21,345.30
growth rate -7.4% 2.2% 3.7% 4.7% 8.3% 12.0%
R&D 3,874.05
4,072.58
4,267.95
5,051.20
5,595.00
6,085.70
7,025.90
growth rate 5.1% 4.8% 3.4% 10.8% 8.8% 15.5%

Quarterly Statements

Item Name Jun '21 Sep '21 Dec '21 Mar '22 Jun '22
Earnings BIT 1,922.50
2,127.80
2,375.50
2,663.20
1,744.80
growth rate 10.7% 11.6% 12.1% -34.5%
Balance Sheet Jun '21 Sep '21 Dec '21 Mar '22 Jun '22
Acct.Receivable 6,869.70
6,992.30
8,112.50
7,763.60
7,608.40
growth rate 1.8% 16.0% -4.3% -2.0%
Acct.Payable 1,597.80
1,566.80
1,670.60
1,433.30
1,659.30
growth rate -1.9% 6.6% -14.2% 15.8%
Cur.Assets 17,295.50
17,808.30
18,452.40
16,964.70
17,115.20
growth rate 3.0% 3.6% -8.1% 0.9%
Total Assets 47,809.00
48,187.00
48,806.00
46,919.30
47,063.60
growth rate 0.8% 1.3% -3.9% 0.3%
Cash 3,220.00
3,788.20
3,818.50
2,459.20
2,622.90
growth rate 17.7% 0.8% -35.6% 6.7%
Inventory 3,824.90
3,907.40
3,886.00
3,893.00
3,899.40
growth rate 2.2% -0.6% 0.2% 0.2%
Cur.Liabilities 15,093.20
13,682.00
15,052.70
13,386.00
15,620.60
growth rate -9.4% 10.0% -11.1% 16.7%
Liabilities 41,145.50
40,232.90
39,651.20
37,457.30
38,404.40
growth rate -2.2% -1.5% -5.5% 2.5%
LT Debt 14,777.30
15,557.10
15,387.00
15,196.10
14,782.40
growth rate 5.3% -1.1% -1.2% -2.7%
Equity 6,444.40
7,757.00
8,979.20
9,330.80
8,544.70
growth rate 20.4% 15.8% 3.9% -8.4%
Common Shares 598.10
598.20
596.30
594.10
594.10
growth rate 0.0% -0.3% -0.4% 0.0%
Cash Flow Statement Jun '21 Sep '21 Dec '21 Mar '22 Jun '22
Capital Expenditures 381.30
336.80
291.40
365.40
371.00
growth rate -11.7% -13.5% 25.4% 1.5%
Cash Dividends 768.30
770.40
773.30
885.50
883.70
growth rate 0.3% 0.4% 14.5% -0.2%
Cash From OA 1,775.50
1,631.30
2,156.50
2,499.20
820.70
growth rate -8.1% 32.2% 15.9% -67.2%
FCF 1,394.20
1,294.50
1,865.10
2,133.80
449.70
growth rate -7.2% 44.1% 14.4% -78.9%
Income Statement Jun '21 Sep '21 Dec '21 Mar '22 Jun '22
Sales 6,740.10
6,772.80
7,999.90
7,810.00
6,488.00
growth rate 0.5% 18.1% -2.4% -16.9%
Op.Income 1,922.50
2,127.80
2,375.50
2,663.20
1,744.80
growth rate 10.7% 11.6% 12.1% -34.5%
IBT 1,593.90
1,245.30
1,839.90
2,053.60
1,090.90
growth rate -21.9% 47.8% 11.6% -46.9%
Net Income 1,390.20
1,110.10
1,726.10
1,902.90
952.50
growth rate -20.2% 55.5% 10.2% -49.9%
EPS
growth rate
Gross Profit 5,209.90
5,342.00
5,854.30
5,737.90
5,057.50
growth rate 2.5% 9.6% -2.0% -11.9%
R&D 1,672.80
1,708.90
1,959.40
1,610.10
1,781.90
growth rate 2.2% 14.7% -17.8% 10.7%

Growth Grade & Financial Ratios

All financial ratios below are calculated based on latest annual statements available and present the most up to date snapshot of a company finances.

Growth Grade

Historical Growth Grade:

C (60.42)

YOY Growth Grade:

D (35.64)

Click on buttons above for detailed yearly growth rates.

Market Ratios

Profitability Ratios

Liquidity Ratios

Efficiency Ratios

Value Price

PE and EPS

Historical Current Forward
PE 62.45 59.73 65.17
EPS / Growth 11.5% 5.54 22.8%

Value Price & Investment Recovery Time

Read more about Stock2Own value price in Stock Market: Fundamental Analysis.

Equity Growth Rate: 12.9%

Estimates Pessimistic Moderate Optimistic My Numbers
Rate of Return 15.0%
MOS Price % 50 %
Future EPS Growth 11.5% 15.7% 15.7%
Future PE 23.02 53.03 53.03
Future EPS 16.47 23.90 23.90
Value Price
MOS %
93.72
-71.7%
313.32
-5.3%
313.32
-5.3%
MOS Price 46.86 156.66 156.66
IRT 18.07 15.12 15.12

Graham Number:

NOTE: The Graham Number applies only to certain types of stocks in combination with a number of other criteria.

Read more about Graham Number in Stock Market: Fundamental Analysis.

Price Chart

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.

Risk / Reward Ratios

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.